Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REPLIGEN CORPORATION

(RGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • The company has solid fundamentals for a short-term investment strategy.
Strengths
  • The share is getting closer to its long-term support in weekly data, at USD 166.57, which offers good timing for buyers.
  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The company returns high margins, thereby supporting business profitability.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
  • The group usually releases upbeat results with huge surprise rates.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • For several months, analysts have been revising their EPS estimates roughly upwards.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The stock is in a well-established, long-term rising trend above the technical support level at 166.57 USD
Weaknesses
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • With an expected P/E ratio at 100.59 and 90.67 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
Ratings chart
Sector Other Medical Equipment, Supplies & Distribution
1st jan.Capitalisation (M$)Investor Rating
REPLIGEN CORPORATION-10.45%9 422
ABBOTT LABORATORIES8.13%206 733
MEDTRONIC PLC6.90%165 975
BECTON, DICKINSON AND COMPA..-3.43%70 273
ALIGN TECHNOLOGY, INC.2.67%43 417
HOYA CORPORATION-9.74%43 396
BAXTER INTERNATIONAL INC.3.56%41 787
SARTORIUS STEDIM BIOTECH21.57%39 410
ZIMMER BIOMET HOLDINGS, INC..6.28%34 143
DEXCOM, INC.-9.80%32 249
TERUMO CORPORATION-6.61%27 790
FUJIFILM HOLDINGS CORPORATI..29.04%25 624
AMERISOURCEBERGEN CORPORATI..22.85%24 668
WEST PHARMACEUTICAL SERVICE..14.64%23 978
SYSMEX CORPORATION-13.27%20 530
IMEIK TECHNOLOGY DEVELOPMEN..49.35%19 337
More Results
Financials (USD)
Sales 2021 585 M - -
Net income 2021 97,5 M - -
Net cash 2021 596 M - -
P/E ratio 2021 101x
Yield 2021 -
Capitalization 9 422 M 9 422 M -
EV / Sales 2021 15,1x
EV / Sales 2022 12,6x
Nbr of Employees -
Free-Float 92,9%
Upcoming event on REPLIGEN CORPORATION
08/05/21
Surperformance Ratings©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes